Distribution and Drug Resistance of Acinetobacter baumannii Infection in Tumor Patients

Objective To explore the clinical distribution and drug resistance of Acinetobacter baumannii infection in Hunan Tumor Hospital,and to provide the evidence for rational use of antibiotics in clinical application.Methods Totally 128 strains of Acinetobacter baumannii isolated from clinical samples of inpatients with tumor in Hunan Tumor Hospital from January,2007 to December,2009 were retrospectively analyzed,and the drug resistances to 19 kinds of antibiotics were analyzed too.Results The Acinetobacter baumannii infection occurred mainly in ICU wards,followed by department of internal medicine.The majority of clinical specimens (82.03%) were sputum and throat swabs collected from patients with lung cancer.The drug resistance rates to 19 kinds of antimicrobial agents were on the rise in recent years.The susceptibility rates of Acinetobacter baumannii to meropenem,piperacillin/tazobactam,levofloxacin,and cefepime were all less than 10%,while the susceptibility rates of Acinetobacter baumannii to other 15 kinds of antibiotics were all more than 30%.Conclusions Meropenem is still the first choice for Acinetobacter baumannii infection.The situation of drug resistance of Acinetobacter baumannii is severe,and therefore it is necessary for medical professionals to monitor the drug resistance of bacteria and to reduce the incidence of resistant isolates.